Straits Research Pvt Ltd
Global Astaxanthin Market Size is projected to reach USD 7,536.19 million by 2031, growing at a CAGR of 16.78%: Straits Research
March 13, 2024 09:10 ET | Straits Research Private Limited
New York, United States, March 13, 2024 (GLOBE NEWSWIRE) -- Astaxanthin is produced by the yeast fungus Xanthophyllomyces dendrorhous and the freshwater microalgae Haematococcus Pluvialis....
How Do Companies Ave
How Do Companies Avert Further Frustration among Neurologists Due to Relyvrio’s (Amylyx) Phase 3 Failure and Donanemab’s (Lilly) FDA delay?
March 12, 2024 15:10 ET | Spherix Global Insights
EXTON, PA, March 12, 2024 (GLOBE NEWSWIRE) -- For neurologists tasked with delivering the distressing diagnosis of Amyotrophic Lateral Sclerosis (ALS) or Alzheimer’s Disease (AD), the upcoming...
Replay_Logo_Black_CMYK.png
Replay’s cell therapy product company Syena announces first patient dosed in Phase 1/2 study of TCR-NK cell therapy for multiple myeloma
March 11, 2024 07:00 ET | Replay Bio
Replay’s cell therapy product company Syena announces first patient dosed in Phase 1/2 study of TCR-NK cell therapy for multiple myeloma Phase 1/2 clinical study of NY-ESO-1 TCR/IL-15 NK for relapsed...
NodThera_logo.jpg
NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial
March 07, 2024 07:00 ET | NodThera
NodThera Ltd (“NodThera” or the “Company”) NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial Brain-penetrant NLRP3 inflammasome inhibitor...
OBT-RGB_1417_544 (2).jpg
Oxford BioTherapeutics Announces Launch of Enhanced Discovery Platform, OGAP®-Verify, at World ADC Conference 2024
March 07, 2024 04:00 ET | Oxford BioTherapeutics
OGAP®-Verify allows for significantly enhanced sensitivity and specificity for improved target selection, dramatically accelerating drug target discoveryOGAP-Verify is now more sensitive than...
persica pharma.png
Persica Pharmaceuticals completes recruitment into Modic Trial assessing efficacy of PP353, to treat chronic lower back pain
March 07, 2024 03:00 ET | Persica Pharmaceuticals
Persica Pharmaceuticals completes recruitment into Modic Trial assessing efficacy of PP353, to treat chronic lower back pain London, UK, 07 March 2024 – Persica Pharmaceuticals Ltd, a privately held,...
23andMe_Logo_grey.png
23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
March 05, 2024 16:30 ET | 23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced an oral...
MnM_logo_TM_JPG.JPG
Pharmacogenomics Market is Expected to Reach $5.8 Billion | MarketsandMarkets™
March 04, 2024 07:30 ET | MarketsandMarkets Research Pvt. Ltd.
Chicago, March 04, 2024 (GLOBE NEWSWIRE) -- Pharmacogenomics market in terms of revenue was estimated to be worth $3.5 billion in 2023 and is poised to reach $5.8 billion by 2028, growing at a CAGR...
Perfecting Fill Finish
Berkshire Sterile Manufacturing Announces the Launch of Its Webinar Series, Perfecting Fill Finish
February 28, 2024 13:00 ET | Berkshire Sterile Manufacturing
Lee, MA, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Berkshire Sterile Manufacturing (BSM), a Massachusetts-based fill finish CDMO and subsidiary of Sharp, will launch a webinar series, Perfecting Fill...
Healis Therapeutics' asset CKDB-501A shares Phase III topline results for glabellar injections from CKD Bio in South Korea
February 27, 2024 08:00 ET | Healis Therapeutics
CKDB-501A, a novel BoNT/A neuromodulator protein, completed a Phase 3 trial to investigate the efficacy and safety in treating the glabella.